lacks plausible allegations of anticompetitive
Posted: Mon Dec 23, 2024 6:27 am
Epic also alleges that Particle enabled its customers to access confidential patient records under false pretenses, which, according to the filing, was uncovered by Epic and its healthcare provider clients. Particle Health responded to the motion with confidence. We remain confident that our claims will survive the motion, a company spokesperson said in an emailed statement. Per Fierce Pharma, Epic’s filing contends that Particle failed to establish a clear definition of a relevant antitrust product market, a key component for a successful antitrust claim.
Epic also argues that the lawsuitbehavior. Source: Fierce Pharma poland whatsapp code Qualcomm Secures Partial Victory in Licensing Dispute with Arm, Jury Splits on Key Issues By CPI | December 22, 2024 In a high-stakes legal battle between two chip industry titans, a U.S. federal jury found that Qualcomm’s central processors are properly licensed under an agreement with Arm Holdings, according to Reuters. The verdict removes some uncertainty regarding Qualcomm’s ambitious push into the laptop market, though unresolved questions leave room for future legal wrangling.
The week-long trial in a Delaware federal court ended in a partial resolution, with jurors failing to reach a consensus on one of the three central questions posed to them. The deadlock resulted in a mistrial on that specific issue. Per Reuters, Arm expressed disappointment with the outcome and has vowed to seek a new trial, signaling that the dispute is far from over. Divergent Outcomes and Implications for Both Sides The jury unanimously determined that Qualcomm had not breached its license with Arm, despite concerns about the acquisition of Nuvia, a startup it purchased for $1.
Epic also argues that the lawsuitbehavior. Source: Fierce Pharma poland whatsapp code Qualcomm Secures Partial Victory in Licensing Dispute with Arm, Jury Splits on Key Issues By CPI | December 22, 2024 In a high-stakes legal battle between two chip industry titans, a U.S. federal jury found that Qualcomm’s central processors are properly licensed under an agreement with Arm Holdings, according to Reuters. The verdict removes some uncertainty regarding Qualcomm’s ambitious push into the laptop market, though unresolved questions leave room for future legal wrangling.
The week-long trial in a Delaware federal court ended in a partial resolution, with jurors failing to reach a consensus on one of the three central questions posed to them. The deadlock resulted in a mistrial on that specific issue. Per Reuters, Arm expressed disappointment with the outcome and has vowed to seek a new trial, signaling that the dispute is far from over. Divergent Outcomes and Implications for Both Sides The jury unanimously determined that Qualcomm had not breached its license with Arm, despite concerns about the acquisition of Nuvia, a startup it purchased for $1.